Holen Sie sich die Stockscreener-App
16.83
7.27%
1.14
Schlusskurs vom Vortag:
$15.69
Offen:
$15.65
24-Stunden-Volumen:
132.32K
Relative Volume:
2.20
Marktkapitalisierung:
$121.35M
Einnahmen:
$100.44M
Nettoeinkommen (Verlust:
$-133.16M
KGV:
-0.6533
EPS:
-25.76
Netto-Cashflow:
$-94.85M
1W Leistung:
+34.10%
1M Leistung:
+36.83%
6M Leistung:
+84.54%
1J Leistung:
+38.12%
1-Tages-Spanne:
$15.36
$17.25
1-Wochen-Bereich:
$12.55
$17.25
52-Wochen-Spanne:
$5.005
$18.70
Atara Biotherapeutics Inc Stock (ATRA) Company Profile
Firmenname
Atara Biotherapeutics Inc
Sektor
Branche
Telefon
805-623-4211
Adresse
1280 RANCHO CONEJO BLVD, THOUSAND OAKS, CA
Vergleichen Sie ATRA mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ATRA
Atara Biotherapeutics Inc
|
16.83 | 113.13M | 100.44M | -133.16M | -94.85M | -25.76 |
|
VRTX
Vertex Pharmaceuticals Inc
|
444.64 | 110.88B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
726.21 | 72.79B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
890.11 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
404.46 | 54.85B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
189.85 | 41.41B | 447.02M | -1.18B | -906.14M | -6.1812 |
Atara Biotherapeutics Inc Stock (ATRA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2023-11-09 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2023-11-09 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2023-11-09 | Herabstufung | Mizuho | Buy → Neutral |
| 2022-07-20 | Herabstufung | Citigroup | Neutral → Sell |
| 2022-07-13 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2022-07-13 | Herabstufung | Stifel | Buy → Hold |
| 2022-05-10 | Herabstufung | Citigroup | Buy → Neutral |
| 2021-05-13 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2020-12-09 | Herabstufung | Citigroup | Buy → Neutral |
| 2020-12-08 | Bestätigt | H.C. Wainwright | Buy |
| 2020-11-10 | Bestätigt | H.C. Wainwright | Buy |
| 2020-06-30 | Eingeleitet | Evercore ISI | Outperform |
| 2020-06-15 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-04-23 | Hochstufung | Citigroup | Neutral → Buy |
| 2019-11-08 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2019-09-27 | Herabstufung | Goldman | Neutral → Sell |
| 2019-09-16 | Herabstufung | Jefferies | Buy → Hold |
| 2019-06-04 | Hochstufung | Citigroup | Sell → Neutral |
| 2019-05-30 | Eingeleitet | ROTH Capital | Buy |
| 2019-05-23 | Eingeleitet | Stifel | Buy |
| 2019-01-23 | Eingeleitet | Mizuho | Buy |
| 2018-04-10 | Eingeleitet | JP Morgan | Overweight |
| 2018-03-16 | Eingeleitet | Guggenheim | Neutral |
| 2018-03-05 | Bestätigt | Jefferies | Buy |
| 2018-02-28 | Herabstufung | JMP Securities | Mkt Outperform → Mkt Perform |
| 2018-02-15 | Herabstufung | Citigroup | Neutral → Sell |
| 2018-01-03 | Hochstufung | Citigroup | Sell → Neutral |
| 2017-10-06 | Fortgesetzt | Goldman | Neutral |
Alle ansehen
Atara Biotherapeutics Inc Aktie (ATRA) Neueste Nachrichten
Panic Selling: Why Atara Biotherapeutics Inc stock could be next big winner2025 Buyback Activity & Fast Momentum Stock Entry Tips - BỘ NỘI VỤ
Atara Biotherapeutics Stock Drop Looks Sharp, But How Deep Can It Go? - Trefis
Would You Still Hold Atara Biotherapeutics Stock If It Fell Another 30%? - Trefis
Can Atara Biotherapeutics Stock Recover If Markets Fall? - Trefis
How Atara Biotherapeutics Inc. stock performs during Fed tightening cyclesWeekly Investment Report & Weekly Watchlist of Top Performers - Newser
Can Atara Biotherapeutics Inc. (AT20) stock hit consensus price targetsJuly 2025 Closing Moves & Daily Profit Maximizing Trade Tips - Newser
Is Atara Biotherapeutics Inc. (AT20) stock trading at attractive multiplesJuly 2025 Catalysts & Scalable Portfolio Growth Ideas - Newser
Why Atara Biotherapeutics Inc. (AT20) stock gets analyst attentionPortfolio Gains Summary & Daily Growth Stock Investment Tips - Newser
Is Confidence Futuristic Energetech Limited a Top Alpha Generator for Growth PortfoliosMarket Correction Analysis & Free Real-Time Trading Signals - earlytimes.in
Can Atara Biotherapeutics Inc. stock maintain operating margins2025 Key Lessons & Reliable Breakout Forecasts - Newser
Atara Biotherapeutics (ATRA) Stock Analysis Report | Financials & Insights - Benzinga
Atara Biotherapeutics (NASDAQ:ATRA) Stock Price Passes Below 50 Day Moving AverageHere's Why - MarketBeat
Why Atara Biotherapeutics Inc. (AT20) stock could rally strongly2025 Major Catalysts & Breakout Confirmation Trade Signals - Newser
How robust is Atara Biotherapeutics Inc. (AT20) stock financial positionPortfolio Growth Summary & Accurate Entry and Exit Point Alerts - Newser
Why analysts remain bullish on Atara Biotherapeutics Inc. stockTrade Analysis Report & Expert Curated Trade Setup Alerts - Newser
Can Atara Biotherapeutics Inc. (AT20) stock sustain revenue momentum2025 Trading Recap & Free Long-Term Investment Growth Plans - Newser
Is Atara Biotherapeutics Inc. stock attractive for long term wealth buildingQuarterly Risk Review & Expert Verified Movement Alerts - Newser
Will Atara Biotherapeutics Inc. (AT20) stock benefit from infrastructure billJuly 2025 PostEarnings & Verified Short-Term Plans - Newser
Atara Biotherapeutics: An Empty Pipeline With Little Gas (NASDAQ:ATRA) - Seeking Alpha
Pierre Fabre Pharmaceuticals Announces Transfer from Atara Biotherapeutics of the Biologics License Application (BLA) for Tabelecleucel as Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease (EBV+ PTLD) (PR Newswire) - Aktiellt
Perre Fabre Pharmaceuticals, Inc. Announces Transfer of Investigational New Drug Application for Tabelecleucel from Atara Biotherapeutics, Inc. (PR Newswire) - Aktiellt
Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Receives $21.00 Consensus Target Price from Analysts - Defense World
Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Understanding the Setup: (ATRA) and Scalable Risk - news.stocktradersdaily.com
Mizuho raises Atara Biotherapeutics stock price target on reduced expenses By Investing.com - Investing.com Canada
Atara Biotherapeutics Inc Stock Analysis and ForecastEconomic Indicators Overview & Chat With Other Investors on Daily Signals - earlytimes.in
Is Atara Biotherapeutics Inc a good long term investmentCup and Handle Formations & Budget Friendly Portfolio Growth - earlytimes.in
Mizuho Raises Price Target on Atara Biotherapeutics to $18 From $16, Keeps Outperform Rating - MarketScreener
Will Atara Biotherapeutics Inc. (AT20) stock keep high P E multiplesTrade Risk Assessment & Verified Swing Trading Watchlists - newser.com
Will Atara Biotherapeutics Inc. (AT20) stock sustain uptrend momentumJuly 2025 Opening Moves & Daily Momentum Trading Reports - newser.com
Why Atara Biotherapeutics Inc. stock could see breakout soon2025 Year in Review & Expert Verified Movement Alerts - newser.com
Atara biotherapeutics CEO Nguyen sells $38437 in stock By Investing.com - Investing.com Canada
Can machine learning forecast Atara Biotherapeutics Inc. recoveryMarket Movement Recap & Low Risk Investment Opportunities - newser.com
Is Atara Biotherapeutics Inc. (AT20) stock attractive post correctionMarket Growth Review & Weekly Market Pulse Alerts - newser.com
How Atara Biotherapeutics Inc. (AT20) stock benefits from digital adoptionJuly 2025 Trends & Stepwise Trade Signal Guides - newser.com
Can Atara Biotherapeutics Inc. stock resist market sell offsTrade Volume Report & Risk Controlled Stock Pick Alerts - newser.com
Atara Biotherapeutics Executives Sell Shares for Tax Obligations - TradingView
Is Atara Biotherapeutics Inc. (AT20) stock nearing a technical breakout2025 Pullback Review & Long Hold Capital Preservation Tips - newser.com
Finanzdaten der Atara Biotherapeutics Inc-Aktie (ATRA)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.45%
0.12%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):